News
- Author:
- Sara Freeman
Publish date: October 10, 2012
Major Finding: Median overall survival was 19.5 months in patient given lenalidomide plus docetaxel and prednisone but was not reached in the doce...
News
- Author:
- Sara Freeman
Publish date: October 10, 2012
Major Findings: Abiraterone acetate reduced opiate use by 19%, and enzalutamide the risk of pain progression by 44%.
News
- Author:
- Sara Freeman
Publish date: October 4, 2012
Major Finding: Median overall survival was 30.9 months for T-DM1 and 25.1 months for capecitabine plus lapatinib (hazard ratio = 0.68, P = .0006)....
News
- Author:
- Sara Freeman
Publish date: October 3, 2012
Major Findings: The hazard ratios for disease-free and overall survival comparing 1 year and 2 years of adjuvant trastuzumab in the HERA trial wer...
News
- Author:
- Sara Freeman
Publish date: October 1, 2012
Major Findings: Progression-free survival was 9.4 months using a combination of dabrafenib 150 mg and trametinib 2 mg as compared with 5.8 months ...
News
- Author:
- Sara Freeman
Publish date: August 6, 2012
News
- Author:
- Sara Freeman
Publish date: July 12, 2012
Major Finding: In the nilotinib-treated group, 96.9% of those who achieved BCR-ABL transcript levels of 1% or less and 98.8% of those who achieved...
News
- Author:
- Sara Freeman
Publish date: July 9, 2012
News
- Author:
- Sara Freeman
Publish date: July 2, 2012
News
- Author:
- Sara Freeman
Publish date: June 29, 2012
Major Finding: Crude prevalences of CNS involvement at diagnosis and overall were 0.9% and 4.1%, respectively, with a median time to an event of 1...
News
- Author:
- Sara Freeman
Publish date: June 29, 2012
Major Finding: After multivariate adjustment, 3-year EFS, PFS, and OS were no different in patients who had received radiotherapy for bulky diseas...
News
- Author:
- Sara Freeman
Publish date: June 26, 2012
News
- Author:
- Sara Freeman
Publish date: June 20, 2012
News
- Author:
- Sara Freeman
Publish date: June 19, 2012
Major Finding: Eight of nine patients responded to crizotinib, and four had durable responses lasting more than 6 months.Data Source: Nine adults ...
News
- Author:
- Sara Freeman
Publish date: June 14, 2012
Major Finding: Median progression-free survival was 4.8 months with regorafenib vs.
